Trial Profile
Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record